Legend Biotech announces BCMA CAR-T Therapy Cilta-cel accepted for accelerated assessment in Europe for the treatment of relapsed and/or refractory multiple myeloma
SOMERSET, N.J. — (BUSINESS WIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced today that the Committee for Medicinal Products for